MURATA-MANUFACTURING
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) unveils a significant advancement in the realm of electronic components with the launch of its innovative L Cancel Transformer (LCT). This remarkable product is the first of its kind and can neutralize the equivalent series inductance (ESL) of a capacitor, optimizing its noise-reducing capabilities. Utilizing Murata’s exclusive ceramic multilayer technology, this breakthrough solution allows engineers to reduce system noise while decreasing costs and component count.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240513693449/en/
[Murata Manufacturing Co., Ltd.] L Cancel Transformer(Photo: Business Wire)
As the demand for miniaturized and highly functional electronics increases, the issue of electromagnetic noise is becoming increasingly prominent for many industries. As a noise countermeasure, capacitors are often utilized between the power supply line and ground, but this method is not without its challenges. The noise removal effectiveness of the capacitor is optimal when a capacitor’s impedance is lowest. However, capacitor impedance can rise due to its ESL, particularly at frequencies beyond the self-resonant frequency, undermining the efficacy of the noise cancellation. To minimize this impact, it is common practice to connect numerous capacitors in parallel in order to collectively reduce impedance, at the expense of Bill of Material (BoM) component count and costs.
Murata’s LCT is a revolutionary new concept capable of resolving the longstanding challenge of managing power supply noise and capacitor component count. Murata’s LCT component is specifically engineered to minimize noise within the frequency range of a few MHz to 1GHz. It achieves this by utilizing negative mutual inductance to reduce a noise-reducing capacitor’s ESL and therefore increase the effectiveness of its operation, drastically reducing the number of required capacitors.
By using non-magnetic ceramic multilayer technology in its construction, the LCT ensures stable negative inductance and low DC resistance (maximum 55mΩ) even in the presence of current variations and is suitable for a wide range of applications, including consumer, industrial and healthcare products. Murata’s LCT breakthrough is a result of their extensive multilayer ceramic knowledge and redefines power supply noise reduction circuit design, and minimizes a significant and persistent electronic design challenge.
Each LCT is suitable for temperatures up to temperatures 125oC and since there is no DC superposition characteristic, it can be used with stable negative inductance up to 3A. The surface mount device (SMD) measures just 2.0 x 1.25 x 0.95 mm and is available in tape and reel packing.
“Murata’s new LCT is a true innovation that does not merely improve what is available, but redefines what is seen as a standard noise suppression component by radically redefining the entire concept”, said Masamichi Ando, Vice President Business Incubation Center Corporate Technology & Business Development Unit, at Murata. “With this revolutionary component, engineers will be able to reduce component count, system complexity and costs, helping to both further miniaturize their solutions and reduce its impact on the environment by lowering material consumption.”
Murata’s LCT (Part number: LXLC21HN0N9C0L) is entering production with samples available now. For more information please visit here.
Please contact us for details: contact form
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240513693449/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
